SPK Acquisition Corp. (SPK) to Combine with Varian Bio in $116M Deal

SPK (NASDAQ:SPK) has entered into a definitive combination agreement with oncology company Varian Biopharmaceuticals at an equity value of $116 million. Westport, Connecticut-based Varian Bio is developing novel therapeutics for the treatment of cancer with therapies designed to fight specific tumor types. The combined company is expected to trade on the Nasdaq under the symbol
Read More